MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Lexicon Pharmaceuticals Inc

Closed

SectorHealthcare

0.5 11.11

Overview

Share price change

24h

Current

Min

0.42

Max

0.5

Key metrics

By Trading Economics

Income

31M

-34M

Sales

25M

27M

EPS

-0.09

Profit margin

-127.16

Employees

103

EBITDA

30M

-30M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+900% upside

Dividends

By Dow Jones

Next Earnings

1 maj 2025

Market Stats

By TradingEconomics

Market Cap

100M

206M

Previous open

-10.61

Previous close

0.5

News Sentiment

By Acuity

40%

60%

146 / 386 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Lexicon Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

1 lis 2024, 12:42 UTC

Major Market Movers

Lexicon Pharma Shares Slide Premarket After Negative FDA Panel Vote

Peer Comparison

Price change

Lexicon Pharmaceuticals Inc Forecast

Price Target

By TipRanks

900% upside

12 Months Forecast

Average 5 USD  900%

High 6 USD

Low 4 USD

Based on 4 Wall Street analysts offering 12 month price targets forLexicon Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

4 ratings

2

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

0.3684 / 0.54Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

146 / 386 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.